Where Innovation Meets Impact: MRA 2023 Annual Report
The Melanoma Research Alliance is committed to ending suffering and death due to melanoma by collaborating with all stakeholders to accelerate research, advance cures, and prevent more melanomas.
MRA is a world leader in advancing transformational science that has caused paradigm shifts in what it means to be diagnosed with and treated for melanoma. We’ve directly invested over $150 million towards our lifesaving grants program — and leveraged an additional $415 million from outside partners — to advance our mission.
The innovative research we support isn’t just changing science — it’s giving patients more treatment options that translate to longer, fuller lives.
A person diagnosed with advanced melanoma today has access to 16 FDA-approved treatment options and hundreds of clinical trials that are enrolling patients to further improve our treatment arsenal. And while we still have many challenges ahead of us, the future of melanoma research — and the prognoses for patients facing this disease — have never been brighter.
This progress isn’t just benefiting patients with melanoma, it’s transforming the entire field of oncology. It’s a testament to the innovation and commitment of melanoma researchers that therapies that were conceived of, tested in, and first approved for melanoma are now being used to treat dozens of other cancers.
While we are proud of what we have achieved together, we know that there is still much work to be done. Throughout this report, you’ll find highlights of our most recent accomplishments, as well as stories of the researchers, clinicians, patients, and advocates who make this progress possible. You will also learn about our strategic priorities and goals for the future, as we continue to pursue our vision of a world where no one suffers or dies from melanoma.
We remain profoundly grateful for the patients who participate in research and for the support of our many advocates, donors, volunteers, partner organizations, government allies, and corporate colleagues who work with us to fund cutting-edge research, foster collaboration and innovation, and change the status quo surrounding melanoma prevention and sun safety.
Together, we can continue to accelerate the pace of discovery, translate research findings from the lab into the clinic, and improve the lives of millions of people affected by melanoma.